Hepatitis Delta: on Soft Paws Across Germany

Overview

Journal Infection

Date 2012 Jul 4

PMID 22753115

Citations 11

Authors

C Reinheimer

H W Doerr

A Berger

Affiliations

Soon will be listed here.

Abstract

Introduction: Globally, more than 350 million people are considered to be chronic carriers of the hepatitis B virus (HBV) infection; thereof, 15-20 million of these individuals are thought to be coinfected with hepatitis delta virus (HDV). The clinical course depends on the mode of transmission; whereas coinfection commonly resolves, superinfection aggravates the disease and progresses to chronicity in over 90 % of the cases, which, again, results in cirrhosis.

Objective: Although many tests are performed in HBV carriers, data on the prevalence of anti-HDV-IgG in Germany are only rarely available and outdated. Therefore, we retrospectively evaluated the seroprevalence of anti-HDV-IgG from the results of our routine service.

Materials And Methods: Between January 2000 and October 2011, serum samples from 2,844 patients (carrying hepatitis B surface antigen) admitted to University Hospital Frankfurt am Main, Frankfurt, Germany, were tested for anti-HDV-IgG by enzyme-linked immunosorbent assay (ELISA).

Results: The overall seroprevalence of anti-HDV-IgG in the collective of Frankfurt (n = 2,844) is 7.4 % [95 % confidence interval (CI): 6.4-8.4]. The amount of seropositive men (8.3 %, 95 % CI: 6.9-10) significantly exceeds the female proportion (5.7 %, 95 % CI: 4.3-7.5). The rate of seropositivity to anti-HDV-IgG in this collective of Frankfurt reached a maximum in the year 2003 (10.1 %, 95 % CI: 8.9-11.1). The lowest rate was observable in 2004, where 5.4 % were positive to anti-HDV-IgG.

Conclusion: Of the HBV carriers in Germany, 5-8 % reveal serologic evidence of coinfection with HDV. The vaccination against HBV is the key to prevent HDV infection; therefore, vaccination must strongly be propagated further on.

Citing Articles

Successful Amendment of an Existing Hepatitis B Screening Programme by a Guideline Recommended Hepatitis D Screening in the Primary Care Setting.

Herta T, Joachim-Richter A, Petroff D, Wolk B, Wolffram I, Berg T Aliment Pharmacol Ther. 2024; 61(4):651-657.

PMID: 39628411 PMC: 11754924. DOI: 10.1111/apt.18424.

Epidemiology Pattern, Prevalent Genotype Distribution, Fighting Stigma and Control Options for Hepatitis D in Bulgaria and Other European Countries.

Tsaneva-Damyanova D, Georgieva L Life (Basel). 2023; 13(5).

PMID: 37240760 PMC: 10222293. DOI: 10.3390/life13051115.

Clinical and virological features of chronic hepatitis B in the French national surveillance program, 2008-2012: A cross-sectional study.

Chevaliez S, Roudot-Thoraval F, Brouard C, Gordien E, Zoulim F, Brichler S JHEP Rep. 2022; 4(12):100593.

PMID: 36313185 PMC: 9596732. DOI: 10.1016/j.jhepr.2022.100593.

Combination of Novel Therapies for HDV.

Elazar M, Glenn J Viruses. 2022; 14(2).

PMID: 35215860 PMC: 8877160. DOI: 10.3390/v14020268.

HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection.

Roggenbach I, Chi X, Lempp F, Qu B, Walter L, Wu R Viruses. 2021; 13(9).

PMID: 34578380 PMC: 8473203. DOI: 10.3390/v13091799.

References

Langer B, Frosner G, von Brunn A . Epidemiological study of viral hepatitis types A, B, C, D and E among Inuits in West Greenland. J Viral Hepat. 1997; 4(5):339-49. DOI: 10.1046/j.1365-2893.1997.00063.x. View

Yurdaydin C, Idilman R, Bozkaya H, Bozdayi A . Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010; 17(11):749-56. DOI: 10.1111/j.1365-2893.2010.01353.x. View

Mumtaz K, Ahmed U, Memon S, Khawaja A, Usmani M, Moatter T . Virological and clinical characteristics of hepatitis delta virus in South Asia. Virol J. 2011; 8:312. PMC: 3138432. DOI: 10.1186/1743-422X-8-312. View

Mohammad Alizadeh A, Ranjbar M, Tehrani A, Keramat F, Mamani M, Rezazadeh M . Seroprevalence of hepatitis D virus and its risk factors in the west of Iran. J Microbiol Immunol Infect. 2011; 43(6):519-23. DOI: 10.1016/S1684-1182(10)60080-1. View

C Reinheimer , Allwinn R, Doerr H . Limited prevalence of influenza A/H1N1v antibodies: footprints of the pandemic of 2010. Infection. 2011; 39(2):101-4. DOI: 10.1007/s15010-011-0105-9. View

Rizzetto M . Hepatitis D: thirty years after. J Hepatol. 2009; 50(5):1043-50. DOI: 10.1016/j.jhep.2009.01.004. View

Inoue J, Takahashi M, Nishizawa T, Narantuya L, Sakuma M, Kagawa Y . High prevalence of hepatitis delta virus infection detectable by enzyme immunoassay among apparently healthy individuals in Mongolia. J Med Virol. 2005; 76(3):333-40. DOI: 10.1002/jmv.20363. View

Rizzetto M, Ponzetto A, Forzani I . Hepatitis delta virus as a global health problem. Vaccine. 1990; 8 Suppl:S10-4; discussion S21-3. DOI: 10.1016/0264-410x(90)90207-3. View

Wedemeyer H, Heidrich B, Manns M . Hepatitis D virus infection--not a vanishing disease in Europe!. Hepatology. 2007; 45(5):1331-2. DOI: 10.1002/hep.21590. View

10.

Hadziyannis S . Review: hepatitis delta. J Gastroenterol Hepatol. 1997; 12(4):289-98. DOI: 10.1111/j.1440-1746.1997.tb00424.x. View

11.

Erhardt A, Hoernke M, Heinzel-Pleines U, Sagir A, Gobel T, Haussinger D . Retrospective analysis of chronic hepatitis D in a West German University Clinic over two decades: migratory pattern, prevalence and clinical outcome. Z Gastroenterol. 2010; 48(8):813-7. DOI: 10.1055/s-0028-1109984. View

12.

Thierfelder W, Hellenbrand W, Meisel H, Schreier E, Dortschy R . Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol. 2002; 17(5):429-35. DOI: 10.1023/a:1013792013184. View

13.

Zaki H, Darmstadt G, Baten A, Ahsan C, Saha S . Seroepidemiology of hepatitis B and delta virus infections in Bangladesh. J Trop Pediatr. 2004; 49(6):371-4. DOI: 10.1093/tropej/49.6.371. View

14.

Yamashiro T, Nagayama K, Enomoto N, Watanabe H, Miyagi T, Nakasone H . Quantitation of the level of hepatitis delta virus RNA in serum, by real-time polymerase chain reaction--and its possible correlation with the clinical stage of liver disease. J Infect Dis. 2004; 189(7):1151-7. DOI: 10.1086/382133. View

15.

Cross T, Rizzi P, Horner M, Jolly A, Hussain M, Smith H . The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. 2007; 80(2):277-82. DOI: 10.1002/jmv.21078. View

16.

Rizzetto M, Hoyer B, Canese M, Shih J, Purcell R, Gerin J . delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A. 1980; 77(10):6124-8. PMC: 350226. DOI: 10.1073/pnas.77.10.6124. View

17.

Wedemeyer H, Yurdaydin C, Dalekos G, Erhardt A, Cakaloglu Y, Degertekin H . Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011; 364(4):322-31. DOI: 10.1056/NEJMoa0912696. View

18.

Farci P . Delta hepatitis: an update. J Hepatol. 2004; 39 Suppl 1:S212-9. DOI: 10.1016/s0168-8278(03)00331-3. View

19.

Weber B, Rabenau H, Berger A, Scheuermann E, Staszewski S, Kreuz W . Seroprevalence of HCV, HAV, HBV, HDV, HCMV and HIV in high risk groups/Frankfurt a.M., Germany. Zentralbl Bakteriol. 1995; 282(1):102-12. DOI: 10.1016/s0934-8840(11)80802-9. View

20.

Hughes S, Wedemeyer H, Harrison P . Hepatitis delta virus. Lancet. 2011; 378(9785):73-85. DOI: 10.1016/S0140-6736(10)61931-9. View